about
Effector mechanisms of rejectionImmune-mediated vascular injury and dysfunction in transplant arteriosclerosisCellular islet autoimmunity associates with clinical outcome of islet cell transplantation.Protein extraction and 2-DE of water- and lipid-soluble proteins from bovine pericardium, a low-cellularity tissueAlloprimed CD8(+) T cells regulate alloantibody and eliminate alloprimed B cells through perforin- and FasL-dependent mechanisms.Preoperative selective desensitization of live donor liver transplant recipients considering the degree of T lymphocyte cross-match titer, model for end-stage liver disease score, and graft liver volumeDevelopment of antibodies to human leukocyte antigen precedes development of antibodies to major histocompatibility class I-related chain A and are significantly associated with development of chronic rejection after human lung transplantation.Long-Term Effects of Antibodies against Human Leukocyte Antigens Detected by Flow Cytometry in the First Year after Renal Transplantation.HLA Genotyping and Antibody Characterization Using the Luminex™ Multiplex Technology.CD8+ T cells negatively regulate IL-4-dependent, IgG1-dominant posttransplant alloantibody production.The significance of non-T-cell pathways in graft rejection: implications for transplant toleranceCritical role of effector macrophages in mediating CD4-dependent alloimmune injury of transplanted liver parenchymal cellsPredominance of intraglomerular T-bet or GATA3 may determine mechanism of transplant rejection.Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.The clinical impact of humoral immunity in pediatric renal transplantation.Graft failure after allogeneic hematopoietic cell transplantationChronic alloantibody mediated rejection.Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantationIncidence and clinical significance of de novo donor specific antibodies after kidney transplantation.Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses.Autologous and Allogenous Antibodies in Lung and Islet Cell Transplantation.The Effect of Histological CD20-Positive B Cell Infiltration in Acute Cellular Rejection on Kidney Transplant Allograft Survival.Detection of anti-HLA antibodies by solid-phase assay in kidney transplantation: friend or foe?Clinical relevance of antibody development in renal transplantation.Methodological aspects of anti-human leukocyte antigen antibody analysis in solid organ transplantation.MHC class I and integrin ligation induce ERK activation via an mTORC2-dependent pathway.Allogenic benefit in stem cell therapy: cardiac repair and regeneration.Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg.Role of Sphingosine-1-Phosphate in Transplant Vasculopathy Evoked by Anti-HLA Antibody.Combined induction therapy with rabbit antithymocyte globulin and rituximab in highly sensitized renal recipients.Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.Allogenicity & immunogenicity in regenerative stem cell therapyTreatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by StepHepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients.Panel reactive antibody in thalassemic serum inhibits proliferation and differentiation of cord blood CD34+ cells in vitro.Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations.Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation.Pretransplantation monitoring of HLA antibodies by complement dependent cytotoxicity and Luminex-based assays.Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors.The Role of Monocyte/Macrophage and CXCR3 in Differentiation between Recurrent Hepatitis C and Acute Cellular Rejection Postliver Transplantation.
P2860
Q27027082-1480D79A-85EA-40D8-B786-BC22E9322FBFQ28084366-5D6A1FE9-42AC-4137-AD51-64886A6A1464Q33344421-327E1ACE-0ACA-4F24-931A-62027E94F28FQ33382797-9327B421-534A-4FC7-81B9-F94DE13B8E76Q33601185-1620D9D5-2D6B-4A53-B8E7-16415AB48795Q33627543-C6CAFD23-86A0-4280-895E-F847BE86B64AQ33867260-8C7F3256-1ED8-41D3-A094-5AD44C07AF31Q33974428-EB360A9F-1D83-4811-B8DE-AA2AD88AE334Q34139327-BEF357E1-3DBC-4E67-A878-DB2771EA062CQ34443169-20D3A11B-ECF1-4AAA-AC7B-E9A8FA85BAA0Q34462156-EE6AEF0D-D63A-409B-97F2-2CC8D0ED07B2Q34498297-F2926B5F-3053-47FF-9995-0F4389E32AEFQ34534855-1E19C27F-85F1-41B7-BC30-C531118BDD3EQ36246918-1D5E97DF-4ED5-431D-ABA3-2FC50A5770CCQ36719246-69E7BC88-8523-4A3B-8828-25B97864033CQ37045988-8548D052-5FE4-4BE9-A0DD-950500CCBDD9Q37058050-1A841E5B-4CE8-496E-A8C8-CEC4195A7446Q37267474-A44452EF-C0AA-4EE5-AEC2-BA0DD43DC1E2Q37375622-9454CB9B-5303-4544-801F-5A0DB2C3A43DQ37394650-2218E102-4F83-47F2-A7DC-5A12B39BEDD3Q37528715-54D9A50E-D046-471A-97A3-6873B6E13D8FQ37531824-D04B7022-4FF8-4A0F-A9B4-F6BD83241CC5Q38001495-44250101-0D99-4002-8B7E-54CFFD3525A2Q38079301-165B00BC-3F10-40E4-A20C-D2DD44D78533Q38262909-1CFD0FE0-3925-4AE4-BD73-38DBC66C4C82Q38291044-3B6BC6C5-BF4D-470F-8EFF-176A18E955B6Q38553235-74505488-DEF5-4386-8691-98FBD4DCD109Q39017122-EC23916F-BF76-4CC5-9736-4E1881E7EF05Q40990718-4C54EACE-854A-476E-A40C-A3D8FABAF8BDQ41258755-CA6C6A3E-BE0A-4AC5-9985-F0BF287415CBQ41384256-0938DFEC-EDC4-4C77-A1E2-9EA4626B16E6Q41964852-1DDC888A-CC0F-4ABF-A72F-473039D65E35Q41967328-672B9C06-5881-4007-8E46-E7669E99B536Q44274789-075311AE-34C8-4BF3-8BD6-5C4A66CA9713Q45938991-7B881EAA-C50A-44FC-9490-1199029BFEC5Q46897107-8A708EBD-322D-404E-91FB-699433AEB7FDQ47362322-21684EBF-C98F-4BD6-BFFD-E46790F3AACFQ48300620-3636DBC2-AFAE-4F2F-A113-BEB88320088AQ54361889-7A266B1B-6CBB-4333-BEB2-1BEB65BCB14DQ55023267-42EFAE28-1179-48A6-B7F8-E16FEC750535
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Humoral theory of transplantation: further evidence.
@ast
Humoral theory of transplantation: further evidence.
@en
type
label
Humoral theory of transplantation: further evidence.
@ast
Humoral theory of transplantation: further evidence.
@en
prefLabel
Humoral theory of transplantation: further evidence.
@ast
Humoral theory of transplantation: further evidence.
@en
P1476
Humoral theory of transplantation: further evidence.
@en
P2093
Junchao Cai
Paul I Terasaki
P304
P356
10.1016/J.COI.2005.07.018
P577
2005-10-01T00:00:00Z